Compare CTLP & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTLP | AQST |
|---|---|---|
| Founded | 1992 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 798.9M | 707.6M |
| IPO Year | N/A | 2018 |
| Metric | CTLP | AQST |
|---|---|---|
| Price | $10.75 | $3.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | N/A | ★ $8.83 |
| AVG Volume (30 Days) | 931.8K | ★ 6.3M |
| Earning Date | 02-05-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 371.48 | N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | ★ $312,565,000.00 | $43,397,000.00 |
| Revenue This Year | $16.11 | N/A |
| Revenue Next Year | $14.37 | $43.02 |
| P/E Ratio | $13.43 | ★ N/A |
| Revenue Growth | ★ 12.94 | N/A |
| 52 Week Low | $7.01 | $2.12 |
| 52 Week High | $11.36 | $7.55 |
| Indicator | CTLP | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 52.04 | 26.63 |
| Support Level | $10.68 | $3.17 |
| Resistance Level | $10.79 | $3.55 |
| Average True Range (ATR) | 0.06 | 0.27 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 34.09 | 2.54 |
Cantaloupe Inc is a technology leader powering self-service commerce by offering one integrated solution for payments processing, logistics, and back-office management. The group offers a comprehensive suite of solutions, including micro-payment processing, self-checkout kiosks, mobile ordering, connected point-of-sale (POS) systems, and enterprise cloud software. Its product and services portfolio consists of Card Readers, Self-Service Kiosks, Smart Coolers, Seed Pick Easy, Cantaloupe Go, Cheq, Smart Lock Connect, and Vine Digital Studio. The company derives revenue streams from subscriptions, transaction processing, and equipment sales.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.